Fibroblast News and Research RSS Feed - Fibroblast News and Research

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.
Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento receives funding to advance immunotherapy targeting WISP1 for treatment of IPF

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that it has received funding to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of IPF, which affects more than 100,000 Americans. [More]
FGF proteins play broad roles in wound healing

FGF proteins play broad roles in wound healing

Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don't become injured. If they do, their wounds don't heal properly, a new study shows. [More]
FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim’s nintedanib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). [More]
Personalized medicine for breast cancer patients may be just around the corner

Personalized medicine for breast cancer patients may be just around the corner

For breast cancer patients, the era of personalized medicine may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School. [More]
New method to help patients with cancer, genetic conditions, neurological disorders

New method to help patients with cancer, genetic conditions, neurological disorders

UT Arlington physics researchers may have developed a way to use laser technology to deliver drug and gene therapy at the cellular level without damaging surrounding tissue. The method eventually could help patients suffering from genetic conditions, cancers and neurological diseases. [More]
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]
FGFR1 amplification predicts poor outcome in early-stage NSCLC

FGFR1 amplification predicts poor outcome in early-stage NSCLC

Amplification of fibroblast growth factor receptor 1 is associated with poor clinical outcome in patients with early-stage non-small-cell lung cancer, Swiss researchers report. [More]
Extensive range of iPSC derived neural cells available from AMSBIO

Extensive range of iPSC derived neural cells available from AMSBIO

AMSBIO offers an extensive range of iPSC derived neural cells including normal and Alzheimer's disease neural progenitor cells, and cerebral cortical neurons. [More]
Device used in physics and chemistry reveals dynamics of pervasive pathogen

Device used in physics and chemistry reveals dynamics of pervasive pathogen

If you have it, you probably don't know it. Cytomegalovirus, or CMV, is perhaps one of the biggest pathogens you've never heard of-big, both proportionately and epidemiologically. [More]
Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β). [More]
Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). [More]
New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014. [More]
ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois. [More]
Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014. [More]
ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013. [More]
Study: Functional electrical stimulation promotes neural cell proliferation in brains of rats with cerebral infarction

Study: Functional electrical stimulation promotes neural cell proliferation in brains of rats with cerebral infarction

Previous studies have shown that proliferation of endogenous neural precursor cells cannot alone compensate for the damage to neurons and axons. From the perspective of neural plasticity, Dr. Yun Xiang and co-workers from Sun Yat-sen University in China observed the effects of functional electrical stimulation treatment on endogenous neural precursor cell proliferation and expression of basic fibroblast growth factor and epidermal growth factor in the rat brain on the infarct side. [More]
Cook Medical launches Stemulate Pooled Human Platelet Lysate cell culture media supplement

Cook Medical launches Stemulate Pooled Human Platelet Lysate cell culture media supplement

Cook Medical will introduce its Stemulate Pooled Human Platelet Lysate cell culture media supplement at the 2014 International Society for Cellular Therapy meeting, April 23-26. [More]
Fibroblasts could offer alternative to heart transplants for patients with heart disease

Fibroblasts could offer alternative to heart transplants for patients with heart disease

Fibroblasts, cells long thought to be boring and irrelevant, could offer an alternative to heart transplants for patients with heart disease. [More]
Sprifermin reduces cartilage loss in patients with knee osteoarthritis

Sprifermin reduces cartilage loss in patients with knee osteoarthritis

In a new study in patients with osteoarthritis (OA) of the knee, at 12 months, total femorotibial cartilage thickness loss was reduced in sprifermin (recombinant human fibroblast growth factor 18)-treated knees compared to placebo-treated knees, with effects being significant in the lateral femorotibial compartment but not in the central femorotibial compartment. [More]
Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex’s GKT137831 reverses lung fibrosis in new model of idiopathic pulmonary fibrosis

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the publication of data showing that GKT137831, a first in class NOX1 and 4 inhibitor, was able to reverse lung fibrosis associated with aging in a new model of idiopathic pulmonary fibrosis. [More]